Primary Objective: Objective: To compare MK-2870 plus pembrolizumab versus pembrolizumab monotherapy with respect to DFS as assessed by BICR. DFS: the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first. Secondary Objective: Objective: To compare MK-2870 plus pembrolizumab to pembrolizumab monotherapy with respect to OS. OS: The time from randomization to death due to any cause
What is the full name of this clinical trial?
MK-2870-019: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Respectable Stage II to IIIB NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery